Ensuring Data Integrity: FDA’s Draft Guidance on In Vivo Bioavailability and Bioequivalence Studies

The FDA recently unveiled the draft guidance for the industry titled, “Data Integrity for In Vivo Bioavailability and Bioequivalence Studies.” This draft guidance serves as a framework for maintaining the…

Continue ReadingEnsuring Data Integrity: FDA’s Draft Guidance on In Vivo Bioavailability and Bioequivalence Studies